Harlequins Partners Antiviral Nasal Spray Brand Viraleze

Harlequins has partnered with VIRALEZE, an antiviral nasal spray.

Taking the next step in securing the safety of the Club’s staff and players, Harlequins has partnered with VIRALEZE, an antiviral nasal spray which claims to combat multiple strains of the virus that causes COVID-19.

Harlequins is the first Rugby Club in the UK to partner with VIRALEZE™, which can be used in conjunction with other safety measures, helping to protect the Club’s players and coaching staff.  

VIRALEZE also works against a broad spectrum of other respiratory viruses including common cold viruses, influenza, and RSV (respiratory syncytial virus).

Developed by leading biopharmaceutical company Starpharma, VIRALEZE™ is the only nasal spray containing a specifically designed antiviral active that has been shown in laboratory studies to irreversibly inactivate more than 99.9% of SARS-CoV-2 within one minute.

Harlequins’ Head of Medical Services, Mike Lancaster, said the Quins were delighted to add VIRALEZE to the range of safety measures already in place to protect players from COVID-19.

“Player health is paramount in professional sport and now more than ever, we look to maximise the level of protection we can offer our players. The VIRALEZE partnership is an important additional level of protection for our Men’s and Women’s players against viruses such as flu and coronavirus/SARS-CoV-2.”

Starpharma’s CEO, Dr Jackie Fairley, said: “We are delighted to partner VIRALEZE with Harlequins, an iconic club with such a long and proud history.

“VIRALEZE is an ideal product for a team like the Quins, especially when the Club is playing away requiring team travel, as well as the close contact that is unavoidable in playing and training.

“We hope VIRALEZE brings the Club and its supporters’ greater confidence and peace of mind as they embark on the final matches of this season.”